证券之星消息，1月8日南向资金减持3.9万股雍禾医疗（02279.HK）。近5个交易日中，获南向资金减持 的有5天，累计净减持13.9万股。近20个交易日中，获南向资金减持的有20天，累计净减持50.55万股。 截至目前，南向资金持有雍禾医疗（02279.HK）1620.55万股，占公司已发行普通股的3.08%。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 雍禾医疗集团有限公司是一家投资控股公司，专门从事提供毛发相关医疗服务。该公司提供一站式毛发 医疗服务，涵盖植发医疗、医疗养固、常规养护及其他配套服务。该公司构建了以"雍禾医疗"为核心， 由专业植发品牌"雍禾植发"、医疗养固品牌"史云逊"、女性美学植发品牌"雍禾发之初"，及医学假发品 牌"哈发达"等组成的全产业链品牌矩阵。该公司建立独立的史云逊医学健发中心，为被毛发问题困扰的 患者进行医学检测、诊断与个性化护理治疗，以提供医疗毛发健康管理服务。该公司主要在中国国内市 场开展业务。 ...

雍禾医疗集团有限公司是一家控股公司，专门从事提供毛发相关医疗服务。该公司提供一站式毛发医疗 服务，涵盖植发医疗、医疗养固、常规养护及其他配套服务。该公司构建了以"雍禾医疗"为核心，由专 业植发品牌"雍禾植发"、医疗养固品牌"史云逊"、女性美学植发品牌"雍禾发之初"，及医学假发品 牌"哈发达"等组成的全产业链品牌矩阵。该公司建立独立的史云逊医学健发中心，为被毛发问题困扰的 患者进行医学检测、诊断与个性化护理治疗，以提供更专业的医疗毛发健康管理服务。该公司主要在中 国国内市场开展业务。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 证券之星消息，12月9日南向资金减持5000.0股雍禾医疗（02279.HK）。近5个交易日中，获南向资金减 持的有5天，累计净减持4.7万股。近20个交易日中，获南向资金减持的有20天，累计净减持51.35万股。 截至目前，南向资金持有雍禾医疗（02279.HK）1641.2万股，占公司已发行普通股的3.12%。 ...

Core Viewpoint - Southbound funds have significantly reduced their holdings in Yonghe Medical (02279.HK), indicating a potential shift in investor sentiment towards the company [1][2]. Group 1: Shareholding Changes - On October 21, 2025, southbound funds reduced their holdings by 126,000 shares, representing a decrease of 0.74% [2]. - Over the past five trading days, there has been a cumulative net reduction of 461,000 shares, with reductions occurring on five separate days [1]. - In the last twenty trading days, the total net reduction reached 1,067,000 shares, with reductions on all twenty days [1]. Group 2: Current Holdings - As of now, southbound funds hold 17,006,000 shares of Yonghe Medical, which accounts for 3.22% of the company's total issued ordinary shares [1]. Group 3: Company Overview - Yonghe Medical Group Limited is a holding company specializing in hair-related medical services, offering a comprehensive range of services including hair transplant medical care, medical hair maintenance, routine care, and other supporting services [2]. - The company has established a brand matrix centered around "Yonghe Medical," which includes specialized brands such as "Yonghe Hair Transplant," "Shiyunxun" for medical hair maintenance, "Yonghe Hair Origin" for female aesthetic hair transplant, and "Hafada" for medical wigs [2]. - Yonghe Medical primarily operates in the domestic market of China, providing professional medical hair health management services through its independent Shiyunxun Medical Hair Health Center [2].

Core Insights - Yonghe Medical (02279) reported a mid-term performance for the six months ending June 30, 2025, with revenue of RMB 862 million, a gross profit of RMB 550 million, representing a year-on-year increase of 3.9% [1] - The company achieved a net profit attributable to shareholders of RMB 27.913 million, marking a turnaround from a loss in the previous year, with earnings per share of RMB 0.06 [1] Company Overview - Yonghe Medical is a leading medical group in China specializing in hair medical services, offering a one-stop solution that includes hair transplantation, medical hair care, routine maintenance, and other related services [1] - The company has established a comprehensive brand matrix centered around "Yonghe Medical," which includes specialized brands such as "Yonghe Hair Transplant," "Shiyunxun" for medical hair care, "Yonghe Fazhichu" for women's aesthetic hair transplantation, and "Hafada" for medical wigs [1] Market Presence - As of June 30, 2025, the company operates 63 hair transplant medical institutions across 61 cities in China, making it the largest and most widely covered chain of hair medical services in the country [1] - The company served a total of 64,845 consumers during the six-month period ending June 30, 2025 [1]

Company Overview - Yonghe Medical Group Limited is a medical group providing one-stop hair medical services, focusing on the hair medical service market since 2005 [3] - The company has established a brand matrix including "Yonghe Medical," "Yonghe Hair Transplant," "Shiyunxun," "Yonghe Fazhichu," and "Hafada" [3] - As of June 30, 2023, the company operates 72 hair transplant medical institutions across 68 cities in China [3] - The company has built a professional medical team of over 1,600 members, including more than 300 registered doctors and over 1,000 nurses [3] Financial Performance - For the fiscal year ending December 31, 2024, Yonghe Medical reported total revenue of 1.804 billion yuan, a year-on-year increase of 1.53% [2] - The company recorded a net profit attributable to shareholders of -226 million yuan, showing a significant year-on-year increase of 58.58% [2] - The gross profit margin stands at 60.08%, while the debt-to-asset ratio is 58.65% [2] Stock Performance - Over the past month, Yonghe Medical's stock has increased by 73.45%, and year-to-date, it has risen by 117.78%, outperforming the Hang Seng Index's increase of 19.1% [2] - As of the latest trading session, the stock price was 2.22 HKD per share, reflecting a 13.27% increase with a trading volume of 3.186 million shares and a turnover of 6.9939 million HKD [1] Industry Valuation - The average price-to-earnings (P/E) ratio for the healthcare equipment and services industry is -2.53 times, with a median of 0.38 times [3] - Yonghe Medical's P/E ratio is -4.21 times, ranking 89th in the industry [3] - Comparatively, other companies in the sector have P/E ratios such as Giant Star Medical Holdings at 0.28 times, Jingjiu Kangliao at 0.38 times, and others ranging up to 5.35 times [3]

Group 1 - The core viewpoint of the news highlights the recent performance of Yonghe Medical, which saw a stock price increase of 9.38% on May 9, closing at 1.05 HKD per share, while the Hang Seng Index rose by 0.4% to 22867.74 points [1] - Over the past month, Yonghe Medical has experienced a cumulative increase of 1.05%, and a year-to-date increase of 6.67%, which is lower than the Hang Seng Index's increase of 13.54% [2] - Financial data shows that as of December 31, 2024, Yonghe Medical achieved total revenue of 1.804 billion RMB, a year-on-year increase of 1.53%, and a net profit attributable to shareholders of -226 million RMB, a year-on-year increase of 58.58%, with a gross margin of 60.08% and a debt-to-asset ratio of 58.65% [2] Group 2 - Currently, there are no institutional investment ratings for Yonghe Medical, and the average price-to-earnings (P/E) ratio for the healthcare equipment and services industry is -21.69 times, with a median of 0.28 times [3] - Yonghe Medical's P/E ratio stands at -2.06 times, ranking 90th in the industry, compared to other companies such as Giant Medical Holdings at 0.19 times and Jingjiu Health at 0.38 times [3] - Yonghe Medical Group Limited is a medical group providing one-stop hair medical services, focusing on the hair medical service market since 2005, and has established a brand matrix including "Yonghe Medical," "Yonghe Hair Transplant," and others, with 72 hair transplant medical institutions across 68 cities in China as of June 30, 2023 [3]